We recently reported that in ELT3 uterine leiomyoma cells, but not in normal myometrial cells, endothelin (ET)-1 exerts a survival effect insensitive to MAPK3/1(ERK1/2) inhibition. In the present work, we investigated the potential role of MAPK14 (p38) in this ET-1-mediated effect. We demonstrated that, in ELT3, but not in normal myometrial cells, ET-1 activated MAPK14. Data based on pharmacological and siRNA approaches indicate that ETA and ETB receptors contributed to the activation of MAPK14 by ET-1 through a mechanism involving Gi protein, but not PI3-kinase. The inhibition of MAPK3/1 by U0126 did not affect the activation of MAPK14 by ET-1. Conversely, the inhibition of MAPK14 by SB203580 and the down-regulation of MAP2K3/MAP2K6 (kinases upstream of MAPK14) by specific siRNA did not alter the activation of MAPK3/1. These data indicate that MAPK14 was activated by ET-1 independently from MAPK3/1. Furthermore, ET-1 increased protein expression of prostaglandin synthase 2 (PTGS2 or COX2), prostaglandin E2 (PGE2) production, and subsequent ELT3 cell survival. The inhibition of PTGS2 induction and subsequent survival induced by ET-1 required the coinhibition of MAPK14 and MAPK3/1. Our findings provide evidence that ET-1 activated MAPK14 only in ELT3 cells, but not in normal myometrial cells. This MAPK14 activation was required, in addition to MAPK3/1 in ET-1-mediated survival through the COX2/prostaglandin axis, and may explain the absence of ET-1 antiapoptotic effect in normal myometrial cells. Our data reinforce the role of ET-1 and associated signaling pathways in leiomyoma pathology.
INTRODUCTION
Uterine leiomyoma, or ''fibroids,'' are benign smooth muscle tumors originating from the myometrium. These tumors have a reported incidence as high as 77% in women of reproductive age, and are the leading indication for hysterectomy. Common symptoms associated with these tumors are dysmenorrhea, menorrhagia, infertility, and morbidity [1] . Among the limited number of animal models for this human disease, the Eker rat is the best available and characterized preclinical model for leiomyoma. These rats develop leiomyoma with high frequency. Eker rat leiomyomas share many characteristics with the cognate human disease [1] , including frequency, phenotypic properties, hormone responsiveness, and molecular alteration, as reported for TSC2/HMG2 [2, 3] . The list of common gene alterations in rat and human leiomyoma is amplified by a recent microarray study that identifies a highly significant overlap of deregulated gene expression in leiomyoma [4] . An Eker leiomyoma tumorderived cell line (ELT3) has been established. Because this cell line maintained properties of tumors, they have been successfully used in many studies to investigate the regulation of leiomyoma growth [1, 5] .
It is well established that leiomyoma growth is under hormonal control by ovarian steroids and growth factors [1, 6] . Furthermore, using different technical approaches, different groups demonstrated that, in human leiomyoma, endothelin (ET)-1 and ET receptor A (ETA) are up-regulated at the gene level [4, [7] [8] [9] . It has also been demonstrated that ET-1 contributes to human leiomyoma cell proliferation [10] . In rat ELT3 leiomyoma cells, our previous data demonstrated that the ET-1 axis is able to increase cell proliferation [11, 12] and survival [13] .
ETs are a family of structurally homologous 21-amino acid peptidic hormones that include ET-1, ET-2, and ET-3. ETs exert their effects by binding to the cell-surface ETA and ETB receptors, which belong to the G protein-coupled receptor family [14, 15] . ET-1 is produced at the level of the uterine tissues [16] . The ET-1 axis is associated with different physiological and pathological processes, including steroiddependent female malignancies [14, 15] . Our previous data demonstrated that myometrial cells expressed predominantly ETA receptors, while, in ELT3, both ETA and ETB are equivalently coexpressed and up-regulated [11] . This differential ET receptor expression is accompanied by different ETmediated functions. Indeed, in ELT3 cells, ET-1 exerts a stronger proliferative effect, correlated with an increase in phospholipase D activity that contributes to the activation of MAPK3/1, commonly termed ERK1/2 [12] . Furthermore, in ELT3 cells, but not in myometrial cells, ET-1 exerts an antiapoptotic effect that is unaffected by the inhibition of MAPK3/1 [13] .
ET-1 can activate not only MAPK3/1, but also MAPK14 (p38) [17, 18] . The p38 MAPK family of serine/threonine kinases consists of four members (p38a, p38b, p38c, and p38d). Activation of the p38 signaling pathways involves phosphorylation via upstream MAP kinase kinases (MAP2K) 3/6/4/7 or TAK1 and ASK1. Alternatively, p38 can be activated by its interaction with TAB-1 [19] . Phosphorylation of both threonine and tyrosine at a conserved TGY motif is associated with p38 activation that regulates downstream targets. The activation of p38 MAPK has generally been associated with cellular stress, inflammation, and apoptosis [20] . However, it has been reported that activated p38 also contributes to cell proliferation [21] and cell survival [22] . The analysis of human leiomyoma gene expression profiling indicated that members of the p38 family, at least MAPK12 [23] and MAPK14 genes [24] , are up-regulated in human leiomyoma.
The expression of prostaglandin synthase (PTGS2), usually termed cyclooxygenase 2 (COX2), can be regulated by MAPK3/1 and/or p38 [25] [26] [27] [28] . The expression of COX2, the inducible form of COX, is enhanced by different stimuli, including growth factors, proinflammatory cytokines, lipopolysaccharides, and steroid hormones [29, 30] . This enzyme catalyzes the production of prostaglandins (PGI2, PGE2, PGF2a. . .), which play an important role in uterine physiology and pathology [14, 29] . It has been demonstrated that, in primary leiomyoma tumors and leiomyoma-derived ELT3 cells, PTGS2 expression and subsequent PGE2 production are up-regulated [31] . Furthermore, PTGS2 expression plays a crucial role in leiomyoma growth in an in vivo model [32] .
With this background, we investigated the possible activation of MAPK14 by ET-1, the mechanism by which this activation may occur, its potential role in PTGS2 induction, and ET-1-mediated ELT3 leiomyoma cell survival in comparison with myometrial cells.
MATERIALS AND METHODS

Chemicals
ET-1 and Sarafotoxin 6c (S6c) were from Neosystem (Strasbourg, France). Epidermal growth factor (EGF), Worthmanin, LY294002, pertussis toxin, anisomycin, anti-a tubulin, PGE2, and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylltetrazolium (MTT) were obtained from Sigma-Aldrich (Saint Quentin Fallavier, France). SB203580 was from Calbiochem (Fontenay sous bois, France). Anti-phospho-MAPK14 (p38) (Thr180/Tyr182), anti-phospho-MAPK3/1 (ERK1/2) (Thr202/Tyr204), U0126, Apo-One homogeneous caspase-3/7 assay, and PD98059 were from Promega Corp. (Charbonniers, France). Anti-MAPK1 (ERK2) and anti-total p38 (MAPK14) antibodies were from Santa Cruz biotechnology (Santa Cruz, CA). Rabbit anti-PTGS2 (COX2) was from Cayman Chemical Co. (Ann Arbor, MI). PGE2 expression EIA kits were from Coger (Paris, France). Anti-rabbit HRP-conjugated IgG was from Ozyme (Montigny le Bretonneux, France). ECL reagents were purchased from Perkin Elmer (Courtaboeuf, France). Control siRNA were synthesized by MWG-Biotech (Ulis, France). Rat ETA-, ETB-, MAP2K3-, and MAP2K6-directed siRNA (si GENOME ON-TARGET plus SMARTpool L-089698-01, L-089829-01, L083654-01, and L098486-01, respectively) were from Dharmacon (Thermofisher, UK). Cell line, Nucleofector kit V was from Lonza (Verviers, Belgium). The bicinchoninic assay protein kit was from Perbiosciences (Brebieres, France). All of the media and reagents for the cell culture were from Invitrogen (Cergy Pontoise, France).
Myometrial Cell Culture
Primary cultures of myometrial cells were prepared by collagenase digestion of rat myometrium, as previously described [12] . The Eker rat tumor-derived ELT3 uterine leiomyoma cell line was kindly provided by Dr. C. L. Walker (M. D. Anderson Cancer Center, University of Texas, Smithville, TX). Primary myometrial cells and ELT3 cells were cultured in DF8 medium supplemented with 10% (v/v) fetal calf serum, and maintained in 5% CO 2 /95% humidified air at 378C, as previously described [12] . Cells were placed in serum-free medium 16 h before experiments.
Cell Incubations
Serum-starved confluent myometrial cells seeded on 12-well plates were incubated with agents tested for the indicated times. Reactions were stopped by aspiration of the incubation medium followed by the addition of 50 ll of cold solubilization buffer (50 mM HEPES [pH 7.4], 150 mM NaCl, 100 mM NaF, 10% [v/v] glycerol, 10 mM Na4P2O7, 200 lM Na3VO4, 10 mM EDTA, 1% (v/v) Triton-X100, 10 lg/ml aprotinin and leupeptin, and 0.5 mM PMSF). Cells were detached by scraping on ice and centrifuged at 10 000 3 g for 5 min at 48C. The resulting supernatants (detergent-extracted proteins) were used for protein analysis (MAPK3/1, MAPK14, and PTGS2) and protein assay (using bicinchoninic assay kit). For desensitization experiments, cells were pretreated with agonist for the indicated times. After washing, incubation continued in fresh medium, and cells were stimulated with indicated agonists for 5 min. 
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Western Blot Analysis
Detergent-extracted proteins were analyzed by 10% (w/v) SDS-PAGE. The separated proteins were transferred to nitrocellulose sheets and probed with polyclonal anti-phospho-MAPK3/1 (ERK1/2) antibodies (1:5000, v/v), antiphospho-MAPK14 (p38) (1:1000, v/v), anti-PTGS2 (COX2) antibody (1:10 000, v/v), and HRP-conjugated anti-rabbit IgG secondary antibody (1:2000, v/v). Blots were revealed by ECL technique and exposed on x-ray films. The blots were then stripped and reprobed with anti-total MAPK3 (ERK1) antibodies (1:5000, v/v) or anti-total p38 (MAPK14) antibodies (1:20 000, v/v) and HRP-conjugated anti-rabbit IgG secondary antibody. Quantification of the developed film was performed with a Personal Densitometer (Molecular Dynamics).
RNA Interference
ELT3 cells were harvested by trypsinization and electroporated with an Amaxa Nucleofector device (program T 030) at a density of 10 6 cells in 100 ll of buffer V containing 5 lM of control-, ETA-, or ETB-directed siRNA, and 2 lM of MAP2K3-or MAP2K6-targeted siRNA, or a mix of MAP2K3-and MAP2K6-directed siRNA, according to the manufacturer's instructions. Cells were serum starved 24 h after electroporation. In these experimental conditions, ETA and ETB mRNA was reduced [11] . For siRNA directed against MAP2K3/ MAP2K6, the efficacy was evaluated by the inhibition of MAPK14 phosphorylation and its subsequent function.
PGE2 Production
ELT3 cells were seeded in 24-well plates in 500 ll of growth medium. Following an overnight attachment period, cells were serum starved for 16 h and then treated for 4 h in the absence or presence of the inhibitors and/or agonists indicated in the legend of the corresponding figure. The level of PGE2 released in the medium by ELT3 cells was evaluated by PGE2 ELISA according to the manufacturer's instructions. For each medium, the concentration of produced PGE2 was normalized against total proteins measured in the corresponding cell extract. PGE2 assays were performed in triplicate for three independent experiments.
MTT Assay
ELT3 cells (12 000 cells/well) seeded in 96-well plates were incubated in 200 ll growth medium. Following an overnight period, cells were serum starved for 16 h in 100 ll serum-free medium and treated with different inhibitors in the absence or presence of agonists for the indicated times. At the end of the treatment, 20 ll of MTT (5 mg/ml) was added to each well and the plates were incubated at 378C for 4 h to allow MTT to form formazan crystals by reacting with metabolically active cells. The formazan crystals were solubilized overnight at 378C in 120 ll of lysis buffer (11 g SDS, 50 ml H 2 O, 50 ml isopropanol and 0.02 M HCl). After 18 h incubation at 378C, the culture medium was used to determine the intensity of dye conversion (which is proportional to the number of living cells) spectrometrically at 590 nm using a Wallac 1420 plate reader (Perkin Elmer). For each treatment, the number of living cells was expressed as the percent of nontreated cells. MTT assays were performed in triplicate.
Caspase-3/7 Activity Assay ELT3 Cells were plated in 96-well plates, seeded at a density of 7000 cells per well, and grown until confluence. Cells were then serum starved and incubated in 200 ll of minimum essential medium in the presence or absence of inhibitors or agonists for the indicated times. A caspase assay was performed using the Apo-ONE homogeneous caspase-3/7 assay, according to the manufacturer's instructions and as we have previously described [13] . Briefly, 150 ll of medium was carefully removed from the upper part of the well (to avoid aspiration of floating cells) and 50 ll of lysis buffer containing the fluorogenic Z-DEVD-R110 substrate was added to each well. Fluorescent product formation was measured every 6 min over a 120-min period using a Wallac 1420 Perkin Elmer plate reader set at 378C (excitation at 499 nm and emission at 521 nm). The amount of fluorescent product generated is proportional to the amount of caspase-3/7 cleavage activity present in the sample. At the end of the caspase assay, the lactate dehydrogenase content in each lysate was determined (using the reaction of b-NADH oxidation in the presence of pyruvate, according to the manufacturer's instructions) to evaluate the quantity of cells contained in each well. Caspase-3/7-specific activity was expressed as the ratio of caspase activity (slope of the kinetic activity) to the corresponding lactate dehydrogenase activity (slope of the kinetic activity). Each experimental condition tested was performed in triplicate.
Statistical Analysis
Results are expressed as the mean 6 SEM of at least three independent experiments performed in duplicate or triplicate. Statistical analysis was performed using one-or two-way ANOVA followed by post hoc comparisons with the Fisher LSD test. Values with P , 0.05 were considered as statistically significant.
FIG. 2. ET-1 activates MAPK14 through ETA and ETB.
A) ELT3 cells were pretreated (Pre-treat) or not for 30 min with 50 nM ET-1 or 50 nM S6c. The media were changed and cells were incubated for 5 min without or with 50 nM ET-1 or 50 nM S6c (treat). Phosphorylation of MAPK14 was analyzed as described in Figure 1 . Blot is representative of three independent experiments. B) ELT3 cells, after transfection with control (CTR)-, ETA-, or ETB-targeted siRNA, were serum starved and treated for 5 min with or without 50 nM ET-1 or 50 nM S6c. P-MAPK14 and total MAPK14 were quantified as described in Figure 1 . Results (over basal values) are expressed in arbitrary units (AU). Values are the mean 6 SE of three separate experiments. *P , 0.05 vs. control siRNA treated with ET-1; 
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RESULTS
Activation of MAPK14 in ELT3 Leiomyoma, but Not in Normal Myometrial Cells by ETs
We investigated the potential role of ET-1 in the regulation of the MAPK14 (p38) pathway in normal myometrial cells and uterine leiomyoma cells. Data in Figure 1A demonstrate that, for the same amount of protein extracts, the level of total MAPK14 was equivalent in normal myometrial and ELT3 cells. However, in normal myometrial cells, the activation of MAPK14 by ET-1 (ETA and ETB agonist) was very weak. As expected, the effect of S6c (ETB agonist) was barely detectable due to the quasi-absence of ETB receptors in these cells [11, 33] . The data revealed that, in ELT3 cells, ET-1 and S6c activated MAPK14. The kinetics of MAPK14 activation by ET-1 and S6c presented a similar pattern (Fig. 1B) . This activation was transient, peaked at 3-5 min, and declined progressively to barely detectable levels at 15 min. Maximal S6c effect represented only 60% of ET-1 response, suggesting the contribution of both ETA and ETB receptors.
Contribution of ETA and ETB in the Activation of MAPK14 by ET-1
The contribution of ETA and ETB was confirmed by different approaches. We first performed desensitization experiments to down-regulate ETA/ETB or ETB by prolonged treatment with ET-1 or S6c, respectively. The data ( Fig. 2A) demonstrate that prolonged treatment of ELT3 cells with ET-1 abolished subsequent MAPK14 activation by ET-1 and S6c. By contrast, when cells were pretreated with S6c, the subsequent response of S6c was abolished, while the ET-1 effect was only reduced. The contribution of ETA and ETB was confirmed by their down-regulation by the RNA interference technique. The data (Fig. 2B) show that, in ELT3 cells transfected with control siRNA, ET-1 and S6c enhanced MAPK14 phosphorylation, ET-1 being more efficient as observed in nontransfected cells. Treatment with ETAtargeted siRNA reduced ET-1-mediated MAPK14 phosphorylation by 34.6 % 6 0.5, indicating that ETA was implicated. This ETA siRNA treatment did not affect S6c response, reflecting the specificity of ETA siRNA. Treatment of ELT3 cells with ETB siRNA decreased the activation of MAPK14 by S6c (51.9 % 6 0.8). In this condition, the ET-1 response was also reduced (30%). These data indicate that ETA and ETB contributed to the activation of MAPK14 by ET-1.
Involvement of Gi but Not PI3-Kinase in the Activation of MAPK14 and MAPK3/1 by ET Receptors
We previously reported that in normal myometrial rat cells, the activation of MAPK3/1 by ET-1 is dependent on Gi proteins and PI3-kinase [33] . We demonstrated that treatment of ELT3 cells with pertussis toxin (PTX), which prevents receptor/Gi coupling, reduced not only MAPK3/1, but also MAPK14 activation by ET-1 and S6c (Fig. 3A) . However, the S6c (ETB agonist) response was totally inhibited when the ET- 1 response was partially reduced. This result suggests that ETB receptors were preferentially coupled to Gi in the MAPK14 activation. PTX treatment did not alter the responses of EGF used as control for PTX specificity. Furthermore, our data indicate that, in ELT3 cells, ET-1 and S6c activated MAPK14 and MAPK3/1 by a mechanism insensitive to the inhibition of PI3-kinase by worthmanin or LY294002 (Fig. 3B) , whereas these inhibitors were effective on ET-1-mediated MAPK3/1 activation in normal myometrial cells [33] . These data indicate that ETA and ETB receptors activated MAPK3/1 and MAPK14 via their coupling to the Gi protein family, but independently of PI3-kinase activity.
Activation of MAPK14 Independent of MAPK3/1
The results from Figure 3 demonstrate that MAPK3/1 and MAPK14 were similarly regulated by ET-1. This may suggest that their activation by ET receptors can occur by a sequential process. To investigate this possibility, cells were incubated in the presence of MEK inhibitors (U0126 and PD 98059) before the addition of agonists. Results demonstrate that the activation of MAPK14 by ET-1 or S6c was unaffected (Fig. 4A ) when MAPK3/1 were inhibited. Data in Figure 4B indicate that MAPK3/1 activation by ET-1 or S6c was inhibited by U0126, but was not affected by the inhibition of the MAPK14 pathway by SB203580. This pharmacological study was completed by down-regulation of MAP2K3 and MAP2K6 (p38 upstream kinases) expression by specific siRNAs. When ELT3 cells were treated with MAP2K3/6-targeted siRNA, the phosphorylation of MAPK14 by ET-1 or S6c was markedly reduced, while MAPK3/1 response remained unaffected (Fig. 4C) . A mix of MAP2K3 and MAP2K6 siRNA was used because it was more effective to inhibit MAPK14 phosphorylation by anisomycin (p38 activator) than using each siRNA alone (data not shown). Data in Figure 4D show that forskolin (adenylyl cyclase activator) was able to activate MAPK14, but not MAPK3/1. Furthermore, anisomycin activated MAPK14, but not MAPK3/1 at different times tested (Fig. 4E) . These data confirm that MAPK14 and MAPK3/1 were not sequentially activated, and that no direct crosstalk occurred between MAPK3/1 and MAPK14 signaling pathways activated by ET-1 or S6c. Figure 1 . D) ELT3 cells were serum starved and then stimulated for 5 min with 50 nM ET-1 or S6c or 10 lM forskoline (Frsk). Phosphorylated MAPK14 and p-MAPK3/1 were detected as described in Figure 1 . E) ELT3 cells were serum starved for 18 h and then stimulated with 2.5 ng/ml anisomycin or 50 nM ET-1 for the indicated time. Phosphorylated MAPK14 and p-MAPK3/1 were detected as described in Figure 1 . Typical blots representative of three experiments are shown.
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Involvement of MAPK14 and MAPK3/1 in PTGS2 Up-Regulation
In ELT3 cells, it has been shown that PTGS2 (COX2) expression and subsequent PGE2 production are up-regulated [31] . PTGS2 expression is regulated by different MAPK [26, 27] . Therefore, we investigated if the expression of PTGS2 was regulated by ET-1 and related MAPK in ELT3 cells. Data in Figure 5A indicate that ET-1 (ETA/ETB agonist), as well as S6c (ETB agonist), increased the expression of PTGS2 in ELT3 cells. This effect was time dependent, and reached a maximal value at 4 h. The up-regulation of PTGS2 by ET-1 and S6c was reduced in the presence of SB203580 or U0126 and completely abolished in the presence of the two inhibitors (Fig. 5B) . This indicates that the induction of PTGS2 by ETA and ETB activation required the costimulation of MAPK14 and MAPK3/1. The induction of PTGS2 by ET-1 was accompanied by a marked increase of PGE2 production (Fig. 5C) , which was markedly reduced in the presence of SB203580 and U0126. PGE2 production was abolished when MAPK14 and MAPK3/ 1 were coinhibited. These data indicate that, in ELT3 cells, the activation of MAPK14 and MAPK3/1 contributed to the upregulation of PTGS2 expression and activation by ET-1.
Requirement of MAPK14 and MAPK3/1 in ET-1-Mediated ELT3 Cell Survival
We previously reported that, in ELT3 (but not in normal myometrial cells), ET-1 prevents ELT3 cells from apoptosis due to caspase-3/7 activation induced by serum starvation [13] . It has been reported that PGE2 can be a survival factor [34, 35] . We demonstrate that, in ELT3 cells, exogenous PGE2, similar to ET-1, inhibited caspase-3/7 activation due to serum starvation (Fig. 6A) . Data from Figures 5 and 6A suggest that the PTGS2/PGE2 axis could contribute to the ET-1-mediated survival effect. We next analyzed the potential role of MAPK14 in the antiapoptotic effect of ET-1. Data presented in Figure 6A demonstrate that SB203580 or U0126 did not prevent the caspase-3/7 inhibition by ET-1 and PGE2. This result may suggest that MAPK14 or MAPK3/1 was not involved in the antiapoptotic effect of ET-1. Because the inhibition of ET-1-mediated PTGS2 induction required coinhibition of MAPK3/1 and MAPK14, we tested the impact of this treatment on the survival effect of ET-1. When ELT3 cells were incubated with SB203580 þ U0126, the inhibition of caspase-3/7 by ET-1 was markedly reduced (Fig. 6B) . The reduction of the ET-1-mediated survival effect in the presence of SB203580 þ U0126 was not due to ELT3 cell death that can be assigned to the toxicity of the inhibitors. Indeed, cell 
500
OYENIRAN AND TANFIN number was not reduced by the treatment of ELT3 cells by these pharmacological agents (Fig. 6C) . Furthermore, the presence of SB203580 þ U0126 in the incubation medium failed to impair the survival effect of PGE2 (Fig. 6B) . These data provide evidence that MAPK14 cooperated with MAPK3/ 1 to induce the antiapoptotic effect of ET-1 in ELT3 cells.
DISCUSSION
We recently reported that, in ELT3 cells, but not in normal myometrial cells, ET-1 exerts an antiapoptotic effect unaffected by the inhibition of MAPK3/1 (ERK1/2) [13] . In the present study, we demonstrate for the first time that, in addition to MAPK3/1, ET-1 activated MAPK14 (p38) via ETA and ETB. ET-1-mediated ELT3 cell survival required coactivation of both MAPK. ET-1 activated MAPK14 in ELT3 leiomyoma cells, but not in normal myometrial cells that still expressed an equivalent level of MAPK14 proteins. Such a phenomenon has been observed in endometriotic cells, where MAPK14 phosphorylation is higher than in endometrial eutopic tissues [36] . This observation raised questions about the mechanisms involved in the absence of MAPK14 activation in normal myometrial cells. This may be explained by differential MAPK14 isoform expression or by different subcellular localization of MAPK14. Moreover, myometrial cells expressed predominantly ETA [11, 33] . Therefore, it is possible that the MAPK14 activation is related to the additional expression of ETB receptors in ELT3 cells. However, this interpretation is excluded, because, in ELT3 cells, ET-1 (ETA and ETB agonist) retained its ability to activate MAPK14 when ETB receptors were desensitized or down-regulated by specific ETB siRNA. The failure of ETA to activate MAPK14 in normal myometrial cells may be explained by a differential subcellular distribution of ET signaling partners [17, 37] . Alternatively, the absence of MAPK14 activation by ET-1 in myometrial cells may be due to the presence of phosphatase activities that dephosphorylate p38. This interpretation is in line with data from a transcriptomic analysis demonstrating that gene expression of dual-specificity phosphatases, particularly DUSP1:8/10/16 (MAPK14 phosphatases), is down-regulated in human leiomyoma compared to normal human myometrial tissues [4, 38] , as well as in rat Eker leiomyoma [4] . Furthermore, our results provided evidence that, in the presence of ET-1, the phospho-MAPK14/phospho-MAPK3/1 ratio increased in ELT3 cells compared with myometrial cells. 
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The change in this ratio has been observed to be correlated with tumor growth [39] .
We then focused our analysis on the mechanism by which ET-1 activated MAPK14 in ELT3 cells. The kinetics of MAPK14 activation by ET-1 was similar to those reported for MAPK3/1 [12] . Using pharmacological and siRNA approaches, we demonstrate that, as for MAPK3/1, both ETA and ETB contributed to ET-1-mediated MAPK14 activation. Activation of MAPK3/1 and MAPK14 by ET-1 involved Gi proteins, and occurred independently of PI3-kinase. The similar regulation of MAPK3/1 and MAPK14 activation may suggest that ET-1 activated MAPK3/1 and MAPK14 by a common pathway, as reported in different cell models where an MEK-MAPK3/1 pathway is able to stimulate p38 [40] . However, in ELT3 cells, the kinetics of ET-1-mediated MAPK14 activation showed that the maximal ET-1 (acting via ETA and ETB) response was higher than the S6c (acting via ETB) response. This difference was not observed for ET-1 and S6c that induced similar maximal MAPK3/1 activation [11] . This may be due to the activation of different p38 isoforms by ETA and ETB. Alternatively, the additive responses of ETA and ETB at the level of MAPK14 could be due to the contribution of different signaling pathways. This interpretation is supported by our data demonstrating that MAPK14 activation through ETB was mediated by Gi, whereas the ET-1 response was partially Gi mediated. Such an observation is in line with our previous data demonstrating that ETB-mediated phospholipase C activation involved mainly Gi [11] . The activation of MAPK14 by ET-1 was independent of MAPK3/1 activation and vice versa. Indeed, inhibition of the MAPK14 pathway by SB203580 or down-regulation of MAP2K3/MAP2K6 did not alter the activation of MAPK3/1 by ET-1. Conversely, the inhibition of MAPK3/1 by U0126 failed to reduce MAPK14 activation by ET-1. In addition, forskolin, which activates the cyclic AMP/PKA pathway, activated MAPK14, but not MAPK3/1, while anisomycin activated MAPK14, but not MAPK3/1. All these data provide strong evidence that, in ELT3 cells, the activation of MAPK14 by ET-1 is independent of MAPK3/1 activation, but is not sequential as is the case in fibroblasts [41] , platelets [42] , and PC12 cells [43] .
Regarding the functional role of MAPK activation in ELT3 cells, we previously demonstrated that ET-1 induced ELT3 cell proliferation that was totally MAPK3/1 dependent [12] . ET-1 also exerted an antiapoptotic effect that was insensitive to MAPK3/1 inhibition [13] . Our present data reveal the additional activation of MAPK14 by ET-1 in ELT3 cells. Pharmacological inhibition of the MAPK14 pathway, like the inhibition of the MAPK3/1 pathway, failed to reduce the survival effect of ET-1. This may suggest that activated MAPK14 and MAPK3/1 by ET-1 were not involved in ET-1-promoted survival in ELT3 cells. However, our data provide evidence that concomitant inhibition of MAPK14 and MAPK3/1 abolished the survival effect of ET-1. These findings indicate that MAPK14 and MAPK3/1 acted in concert to regulate ELT3 cell survival, and that their coinhibition is necessary to reduce the antiapoptotic effect of ET-1. This could be explained by the convergence of the two MAPKs in the regulation of a common downstream target involved in this survival effect. Therefore, the absence of activated MAPK14 in normal myometrial cells may be related to the absence of ET-1-mediated survival. The involvement of MAPK14 activation in the antiapoptotic effect of ET-1 was recently reported in fibroblasts [22] . In addition, a cooperative effect between MAPK14 and MAPK3/1 regulated other cell functions. Indeed, it has been demonstrated that MAPK3/1 and MAPK14 pathways control migration and in vivo proliferation of melanoma [21] , proliferation of human airway smooth muscle cell [44, 45] , platelet spreading [46] , and activation of transcription factors [47] [48] [49] .
Taking into account that the PTGS2/PGE2 axis plays an important role in myometrial physiology [29, 50] and tumor growth [14] , and that MAPK could regulate the expression of this enzyme [25] [26] [27] , we investigated the potential role of ET-1 and subsequent MAPK3/1/MAPK14 activation in PTGS2 expression. Our data demonstrate that, in ELT3, exogenous PGE2 added in the medium induced an antiapoptotic effect. In addition, ET-1 was able to increase PTGS2 expression and subsequent PGE2 production. These effects were reduced by MAPK14 inhibition. The up-regulation of PTGS2 by ET-1 was also controlled by MAPK3/1. The full inhibition of PTGS2 induction by ET-1 required the coinhibition of MAPK3/1 and MAPK14. As expected, S6c (specific ETB agonist), which activated MAPK14 and MAPK3/1, increased PTGS2 expression. Because S6c and ET-1 are able to rescue ELT3 cells from death due to serum starvation [13] , coactivation of MAPK3/1 and MAPK14 and subsequent PTGS2 induction represented one mechanism by which ET-1, via ETA and ETB, contributed to this ELT3 cell survival. Such a pathway may operate in human leiomyoma, where ET-1 and MAPK14 gene expression is up-regulated [24] . However, so far, the mechanism by which these genes participate in human leiomyoma pathology has not been investigated. Interestingly, in the rat ELT3 leiomyoma cell model, ET-1 axis plays an important role in proliferation [11, 12] and survival [13] , and the use of this cell model 
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allowed us to analyze the molecular mechanisms involved in such ET-1 functions. Since the use of animal cell models has limitations, such functional analysis remained to be validated in human leiomyoma and corresponding normal myometrium cultures that maintain the molecular characteristics of the progenitor tissue phenotype [51] .
The induction of PTGS2 can result from the integration of more than one MAPK pathway in a stimulus-and cell typespecific manner [28] . The involvement of PTGS2 in caspase 3 / 7 inhibition and cell survival has been observed in different human cancers. PTGS2/PGE2 axis inhibits apoptosis via different signaling pathways, including cAMP/PKA [34] and BCL2 expression [35] . PGE2 released in response to ET-1 may contribute to ELT3 survival. However, we noticed that, when PGE2 production was markedly reduced by the inhibition of MAPK3/1 or MAPK14, ET-1 remained able to rescue ELT3 cells from cell death. These data can be explained by a production of other prostaglandins by residual PTGS2 activity. This interpretation is consistent with data indicating that PTGS2-derived prostanoids, such as prostacyclin, thromboxane, or PGF2a, are able to induce cell survival [52] [53] [54] . We previously reported that, in ELT3 cells, the sphingosine-kinase 1/sphingosine 1 phosphate (S1P) pathway contributes to the ET-1-induced antiapoptotic effect [13] . Furthermore, S1P is involved in the up-regulation of PTGS2 in late pregnant rat myometrium [50] and in ELT3 cells (data not shown). Therefore, a potential relationship between PTGS2 and S1P axis may occur in ELT3 cells. This point is currently under investigation.
In conclusion, our results highlight the molecular mechanism by which ET-1 regulated its prosurvival effect by MAPK14 activation in rat leiomyoma, but not in normal myometrial cells. Our data summarized in Figure 7 provide the first evidence that MAPK14 pathway activation cooperates with MAPK3/1 in ET-1-mediated PTGS2 induction, prostaglandin production, and subsequent cell survival. The requirement of different MAPKs in these ET-1 effects may be considered as a compensatory process that would help ELT3 cells to resist cell death.
